ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Radiomics Response Signature for Identification of Metastatic Colorectal Cancer Sensitive to Therapies Targeting EGFR Pathway

Dercle, Laurent*; Lu, Lin; Schwartz, Lawrence H.; Qian, Min; Tejpar, Sabine; Eggleton, Peter; Zhao, Binsheng; Piessevaux, Hubert
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE2020-9DOI: 10.1093/jnci/djaa017
95被引1阅读
引用收藏
分享

摘要

Background: The authors sought to forecast survival and enhance treatment decisions for patients with liver metastatic colorectal cancer by using on-treatment radiomics signature to predict tumor sensitiveness to irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) alone (F) or in combination with cetuximab (FC). Methods: We retrospectively analyzed 667 metastatic colorectal cancer patients treated with F or FC. Computed tomography quality was classified as high (HQ) or standard (SD). Four datasets were created using the nomenclature (treatment) - (quality). Patients were randomly assigned (2:1) to training or validation sets: FCHQ: 78:38, FCSD: 124:62, F-HQ: 78:51, F-SD: 158:78. Four tumor-imaging biomarkers measured quantitative radiomics changes between standard of care computed tomography scans at baseline and 8 weeks. Using machine learning, the performance of the signature to classify tumors as treatment sensitive or treatment insensitive was trained and validated using receiver operating characteristic (ROC) curves. Hazard ratio and Cox regression models evaluated association with over-all survival (OS). Results: The signature (area under the ROC curve [95% confidence interval (CI)]) used temporal decrease in tumor spatial heterogeneity plus boundary infiltration to successfully predict sensitivity to antiepidermal growth factor receptor therapy (FCHQ: 0.80 [95% CI = 0.69 to 0.94], FCSD : 0.72 [95% CI = 0.59 to 0.83]) but failed with chemotherapy (F-HQ: 0.59 [95% CI = 0.44 to 0.72], F-SD : 0.55 [95% CI = 0.43 to 0.66]). In cetuximab-containing sets, radiomics signature outperformed existing biomarkers (KRAS-mutational status, and tumor shrinkage by RECIST 1.1) for detection of treatment sensitivity and was strongly associated with OS (two-sided P < .005). Conclusions: Radiomics response signature can serve as an intermediate surrogate marker of OS. The signature outperformed known biomarkers in providing an early prediction of treatment sensitivity and could be used to guide cetuximab treatment continuation decisions.

学科与关键词

关键词
CONVOLUTIONAL NEURAL-NETWORKRENAL-CELL CARCINOMACOMPUTED-TOMOGRAPHYTUMOR MEASUREMENTSIMATINIB MESYLATERAS MUTATIONSSOLID TUMORSCT SCANSPERFUSIONVARIABILITY
相关
加载中…
  • Coupling radiomics analysis of CT image with diversification of tumor ecosystem: A new insight to overall survival in stage I-III colorectal cancer
    Huang, Yanqi; He, Lan; Li, Zhenhui; Chen, Xin; Han, Chu; Zhao, Ke; Zhang, Yuan; Qu, Jinrong; Mao, Yun; Liang, Changhong*; Liu, Zaiyi*Chinese Journal of Cancer Research, 2022, 34(1).被引 2
  • CT-derived radiomic analysis for predicting the survival rate of patients with non-small cell lung cancer receiving radiotherapy
    Zhang, Nannan; Zhang, Xinxin; Li, Junheng; Ren, Jie; Li, Luyang; Dong, Wenlei*; Liu, Yixin*PHYSICA MEDICA, 2023, 107: 102546.被引 2
  • Non-invasive prediction of microsatellite instability in colorectal cancer by a genetic algorithm-enhanced artificial neural network-based CT radiomics signature
    Chen, Xiaobo; He, Lan; Li, Qingshu; Liu, Liu; Li, Suyun; Zhang, Yuan; Liu, Zaiyi; Huang, Yanqi*; Mao, Yun*; Chen, XinEuropean Radiology, 2023, 33(1): 11-22.被引 5
查看全部 →

发表信息

论文状态
公开发表
期刊
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
发表日期
2020-09
卷期
第 112 卷, 第 9 期
页码
902-912
DOI
10.1093/jnci/djaa017
成果收录
SCIE
资助标注
National Cancer Institute [U01 CA140207, U01 CA225431]; Fondation Philanthropia; Fondation Nuovo-Soldati

作者

  • D

    Dercle, Laurent (通讯) (第一作者)

  • L

    Lu, Lin

查看全部 8 位作者收起作者
  • S

    Schwartz, Lawrence H.

  • Q

    Qian, Min

  • T

    Tejpar, Sabine

  • E

    Eggleton, Peter

  • Z

    Zhao, Binsheng

  • P

    Piessevaux, Hubert

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417